Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Jan 24, 2024

BUY
$12.46 - $29.95 $1,769 - $4,252
142 Added 47.33%
442 $13,000
Q1 2023

Apr 18, 2023

BUY
$3.67 - $4.92 $1,101 - $1,476
300 New
300 $1,000
Q1 2022

Apr 22, 2022

SELL
$4.26 - $7.48 $5,256 - $9,230
-1,234 Closed
0 $0
Q4 2021

Jan 21, 2022

BUY
$4.75 - $7.5 $5,861 - $9,255
1,234 New
1,234 $9,000

Others Institutions Holding IMGN

About ImmunoGen, Inc.


  • Ticker IMGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 220,712,992
  • Description
  • ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...
More about IMGN
Track This Portfolio

Track Allworth Financial LP Portfolio

Follow Allworth Financial LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Allworth Financial LP, based on Form 13F filings with the SEC.

News

Stay updated on Allworth Financial LP with notifications on news.